Total cholesterol/HDL cholesterol ratio and monocyte/HDL cholesterol ratio are related with subclinical hypothyroidism in polycystic ovary syndrome

Abstract

Abstract Objectives There is an association between serum thyrotropin (TSH) and lipid profile. However, there is a little information regarding the relation between subclinical hypothyroidism (SCH), atherogenic indices and inflammation in polycystic ovary syndrome (PCOS). Herein, we aimed to evaluate the impact of SCH on lipids and inflammatory markers in newly diagnosed PCOS patients. Methods Two groups were performed for total 99 PCOS patients: SCH (TSH>2.5 mIU/L) and euthyroid groups (TSH<2.5 mIU/L). Complete blood count, lipids, atherogenic indices were evaluated, inflammatory markers as platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR), monocyte/high density lipoprotein ratio (MHR) and mean platelet volume/platelet ratio (MPR) were calculated. Results SCH group had higher WBC, PLT, PCT, PLR, MPR and non-high density lipoprotein cholesterol levels. Differences between MHR, total cholesterol/HDL cholesterol (TC/HDL), triglycerides/HDL cholesterol (TG/HDL) and low density lipoprotein/HDL cholesterol (LDL/HDL) levels were significantly higher (p=0.001; 0.01; 0.01; 0.02, respectively), TC/HDL cholesterol levels were positively correlated with TSH (p=0.028, r=0.402) in SCH group. TC/HDL levels were also correlated with WBC, PLT, PDW, PCT, MPR and MHR (p=0.003; 0.011; 0.031; 0.037; 0.006; 0.002; r=0.515; 0.442; −0.382; 0.370; −0.471; 0.523, repectively). Conclusions TC/HDL and MHR may serve as beneficial markers for evaluating the inflammatory state of PCOS with SCH. Screening thyroid hormones and curing SCH in PCOS may lower lipids, decelerate developing hypothyroidism and cardiovascular morbidities.